Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2013

01.06.2013 | Pancreatic Tumors

Disparities in Pancreas Cancer Care

verfasst von: Anasooya Abraham, Waddah B. Al-Refaie, Helen M. Parsons, Vikas Dudeja, Selwyn M. Vickers, Elizabeth B. Habermann

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Prior literature shows demographic differences in patients surgically treated for pancreatic cancer (PC). We hypothesized that socioeconomic disparities also exist across all aspects of PC care, in both surgically and non-surgically treated patients.

Methods

We identified a cohort of patients with American Joint Committee on Cancer (AJCC) stage I–IV PC in the 1994–2008 California Cancer Registry. We used multivariate logistic regression to examine the impact of race, sex, and insurance status on (1) resectability (absence of advanced disease), (2) receipt of surgery, and (3) receipt of adjuvant/primary chemotherapy (+/– radiotherapy).

Results

Among 20,312 patients, 7,585 (37 %) had resectable disease; 40 % who met this definition received surgery (N = 3,153). On multivariate analysis, males were less likely to present with resectable tumors [odds ratio (OR) 0.91, 95 % confidence interval (CI) 0.85–0.96], but sex did not otherwise predict treatment. Black patients were as likely as White patients to show resectable disease, yet were less likely to receive surgery (OR 0.66, 95 % CI 0.54–0.80), and adjuvant (OR 0.75, 95 % CI 0.58–0.98) or primary chemotherapy +/– radiation. Compared with Medicaid recipients, non-Medicare/Medicaid enrollees were more likely to receive surgery (OR 1.7, 95 % CI 1.4–2.2), and the uninsured were less likely to receive adjuvant therapy (OR 0.54, 95 % CI 0.30–0.98).

Conclusions

Though Black patients appear to present with comparable rates of resectability, they receive care that deviates from current guidelines. Insurance status is associated with inferior profiles of resectability and treatments. Future policies and research should identify effective strategies to ensure receipt of standard care.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5): 277–300.PubMedCrossRef Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5): 277–300.PubMedCrossRef
3.
Zurück zum Zitat Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007;14(4): 1320–6.PubMedCrossRef Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007;14(4): 1320–6.PubMedCrossRef
4.
Zurück zum Zitat DeLancey JOL, Thun MJ, Jemal A, Ward EM. Recent trends in black-white disparities in cancer mortality. Cancer Epidemiol Biomark Prev. 2008;17(11): 2908–12.PubMedCrossRef DeLancey JOL, Thun MJ, Jemal A, Ward EM. Recent trends in black-white disparities in cancer mortality. Cancer Epidemiol Biomark Prev. 2008;17(11): 2908–12.PubMedCrossRef
5.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246(2): 173–80.PubMedCrossRef Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246(2): 173–80.PubMedCrossRef
6.
Zurück zum Zitat Cress RD, Yin DX, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: A population-based study (United States). Cancer Causes Control. 2006;17(4): 403–09.PubMedCrossRef Cress RD, Yin DX, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: A population-based study (United States). Cancer Causes Control. 2006;17(4): 403–09.PubMedCrossRef
7.
Zurück zum Zitat Riall T, Townsend CJ, Kuo Y, Freeman J, Goodwin J. Dissecting racial disparities in the treatment of patients with locoregional pancreatic cancer: a 2-step process. Cancer. 2010;116(4): 930–9.PubMedCrossRef Riall T, Townsend CJ, Kuo Y, Freeman J, Goodwin J. Dissecting racial disparities in the treatment of patients with locoregional pancreatic cancer: a 2-step process. Cancer. 2010;116(4): 930–9.PubMedCrossRef
8.
Zurück zum Zitat Lucas F, Stukel T, Morris A, Siewers A, Birkmeyer J. Race and surgical mortality in the United States. Ann Surg. 2006;243(2): 281–6.PubMedCrossRef Lucas F, Stukel T, Morris A, Siewers A, Birkmeyer J. Race and surgical mortality in the United States. Ann Surg. 2006;243(2): 281–6.PubMedCrossRef
9.
Zurück zum Zitat Cheung M, Yang R, Byrne M, Solorzano C, Nakeeb A, Koniaris L. Are patients of low socioeconomic status receiving suboptimal management for pancreatic adenocarcinoma?. Cancer. 2010;116(3): 723–33.PubMedCrossRef Cheung M, Yang R, Byrne M, Solorzano C, Nakeeb A, Koniaris L. Are patients of low socioeconomic status receiving suboptimal management for pancreatic adenocarcinoma?. Cancer. 2010;116(3): 723–33.PubMedCrossRef
10.
Zurück zum Zitat Krzyzanowska M, Weeks J, Earle C. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol. 2003;21(18): 3409–14.PubMedCrossRef Krzyzanowska M, Weeks J, Earle C. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol. 2003;21(18): 3409–14.PubMedCrossRef
11.
Zurück zum Zitat Eloubeidi MA, Desmond RA, Wilcox CM, et al. Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg. 2006;192(3): 322–29.PubMedCrossRef Eloubeidi MA, Desmond RA, Wilcox CM, et al. Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg. 2006;192(3): 322–29.PubMedCrossRef
12.
Zurück zum Zitat Shavers VL, Harlan LC, Jackson M, Robinson J. Racial/ethnic patterns of care for pancreatic cancer. J Palliative Med. 2009;12(7): 623–30.CrossRef Shavers VL, Harlan LC, Jackson M, Robinson J. Racial/ethnic patterns of care for pancreatic cancer. J Palliative Med. 2009;12(7): 623–30.CrossRef
13.
Zurück zum Zitat Murphy MM, Simons JP, Hill JS, et al. Pancreatic resection a key component to reducing racial disparities in pancreatic adenocarcinoma. Cancer. 2009;115(17): 3979–90.PubMedCrossRef Murphy MM, Simons JP, Hill JS, et al. Pancreatic resection a key component to reducing racial disparities in pancreatic adenocarcinoma. Cancer. 2009;115(17): 3979–90.PubMedCrossRef
14.
Zurück zum Zitat Arnold L, Patel A, Yan Y, et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity?. Cancer Epidemiol Biomark Prev. 2009;18(9): 2397–405.PubMedCrossRef Arnold L, Patel A, Yan Y, et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity?. Cancer Epidemiol Biomark Prev. 2009;18(9): 2397–405.PubMedCrossRef
15.
Zurück zum Zitat Chang D, Zhang Y, Mukherjee D, et al. Variations in referral patterns to high-volume centers for pancreatic cancer. J Am Coll Surg. 2009;209(6): 720–6.PubMedCrossRef Chang D, Zhang Y, Mukherjee D, et al. Variations in referral patterns to high-volume centers for pancreatic cancer. J Am Coll Surg. 2009;209(6): 720–6.PubMedCrossRef
16.
Zurück zum Zitat Riall T, Eschbach K, Townsend CJ, Nealon W, Freeman J, Goodwin J. Trends and disparities in regionalization of pancreatic resection. J Gastrointest Surg. 2007;11(10): 1242–51; discussion 51-2. Riall T, Eschbach K, Townsend CJ, Nealon W, Freeman J, Goodwin J. Trends and disparities in regionalization of pancreatic resection. J Gastrointest Surg. 2007;11(10): 1242–51; discussion 51-2.
17.
Zurück zum Zitat Epstein A, Gray B, Schlesinger M. Racial and ethnic differences in the use of high-volume hospitals and surgeons. Arch Surg. 2010;145(2): 179–86.PubMedCrossRef Epstein A, Gray B, Schlesinger M. Racial and ethnic differences in the use of high-volume hospitals and surgeons. Arch Surg. 2010;145(2): 179–86.PubMedCrossRef
18.
Zurück zum Zitat Liu J, Zingmond D, McGory M, et al. Disparities in the utilization of high-volume hospitals for complex surgery. JAMA. 2006;296(16): 1973–80.PubMedCrossRef Liu J, Zingmond D, McGory M, et al. Disparities in the utilization of high-volume hospitals for complex surgery. JAMA. 2006;296(16): 1973–80.PubMedCrossRef
19.
Zurück zum Zitat Murphy M, Simons J, Ng S, et al. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(11): 2968–77.PubMedCrossRef Murphy M, Simons J, Ng S, et al. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(11): 2968–77.PubMedCrossRef
20.
Zurück zum Zitat Zell J, Rhee J, Ziogas A, Lipkin S, Anton-Culver H. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomark. Prev 2007;16(3): 546–52.PubMedCrossRef Zell J, Rhee J, Ziogas A, Lipkin S, Anton-Culver H. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomark. Prev 2007;16(3): 546–52.PubMedCrossRef
21.
Zurück zum Zitat Komenaka IK, Martinez ME, Pennington RE, et al. Race and ethnicity and breast cancer outcomes in an underinsured population. J Natl Cancer Inst. 2010;102(15): 1178–87.PubMedCrossRef Komenaka IK, Martinez ME, Pennington RE, et al. Race and ethnicity and breast cancer outcomes in an underinsured population. J Natl Cancer Inst. 2010;102(15): 1178–87.PubMedCrossRef
22.
Zurück zum Zitat Kuhn Y, Koscielny A, Glowka T, Hirner A, Kalff J, Standop J. Postresection survival outcomes of pancreatic cancer according to demographic factors and socio-economic status. Eur J Surg Oncol. 2010;36(5): 496–500.PubMedCrossRef Kuhn Y, Koscielny A, Glowka T, Hirner A, Kalff J, Standop J. Postresection survival outcomes of pancreatic cancer according to demographic factors and socio-economic status. Eur J Surg Oncol. 2010;36(5): 496–500.PubMedCrossRef
23.
Zurück zum Zitat Mulligan CR, Meram AD, Proctor CD, Wu H, Zhu K, Marrogi AJ. Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer. Cancer Epidemiol Biomark Prev. 2006;15(1): 25–31.PubMedCrossRef Mulligan CR, Meram AD, Proctor CD, Wu H, Zhu K, Marrogi AJ. Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer. Cancer Epidemiol Biomark Prev. 2006;15(1): 25–31.PubMedCrossRef
Metadaten
Titel
Disparities in Pancreas Cancer Care
verfasst von
Anasooya Abraham
Waddah B. Al-Refaie
Helen M. Parsons
Vikas Dudeja
Selwyn M. Vickers
Elizabeth B. Habermann
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2843-z

Weitere Artikel der Ausgabe 6/2013

Annals of Surgical Oncology 6/2013 Zur Ausgabe

Healthcare Policy and Outcomes

Comprehensive Databases: A Cautionary Note

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.